On October 7, Novoprotein Scientific Inc. (688137.SH) released an announcement regarding severe abnormal fluctuations in its stock trading and a risk warning, noting that as of the close on September 30, 2026, the company's price-to-sales ratio (TTM) stood at 73.37, significantly higher than that of comparable companies in the same industry.

The company specifically reminded investors to pay attention to secondary market trading risks, make rational decisions, and invest prudently. The company's stock saw its cumulative closing price deviation exceed 30% over three consecutive trading days on September 28, September 29, and September 30, 2026; and from September 16, 2026 to September 30, 2026, the stock's cumulative closing price deviation reached 100% over ten consecutive trading days, constituting a severe abnormal fluctuation in stock trading.

As of the close before the National Day holiday, Novoprotein Scientific Inc. (688137.SH) shares had risen more than 300% year-to-date. According to the company's self-inspection, its current production and operations are normal with no major changes. There have been no significant adjustments in the market environment or industry policies, no major fluctuations in production costs or sales, and internal production and operating order remains normal. There is no undisclosed material information that should be disclosed affecting the abnormal fluctuations in the company's stock trading price.

Novoprotein Scientific Inc. (688137.SH) noted that revenue from RNA vaccine drug-related products accounted for 11.38% of total product revenue in 2025, a relatively low proportion. The company's AI-empowered high-throughput wet lab and data package services are still in the early stages of market expansion, with related business revenue accounting for less than 2% of the company's total operating revenue as of the first half of 2026.

Given that AI applications in the drug research and development industry are still in their infancy, there are risks such as rapid technological iteration, long industry validation cycles, and significant difficulty in commercializing, creating major uncertainty regarding the company's future revenue and profit realization.

The company disclosed its 2026 Semi-Annual Report on August 28, 2026. In the first half of 2026, the company recorded a net loss attributable to owners of the parent company of 29.2045 million yuan, with losses widening by 4.9809 million yuan year-on-year. The company's operating scale is relatively small, and it faces the risk of losses.